Please wait while we take you to your selected region.
Thymosin alpha-1 is a peptide, a small protein-like molecule, first discovered in 1972. It comes from the thymus gland, which helps the immune system by producing T-cells, key players in fighting infections. Since its discovery, thymosin alpha-1 has been studied for conditions like cystic fibrosis, infections (such as tuberculosis and cytomegalovirus), lung issues, chronic hepatitis, and cancer. It’s currently approved in 35 developing countries to treat chronic hepatitis B and C.
Thymosin alpha-1 helps regulate and support the immune system. It influences T-cell development, activates immune pathways, and increases the production of cytokines that help immune cells work together. Studies in mice without thymus glands suggest that thymosin alpha-1 may help restore immune function and improve resistance to infection.
Thymosin alpha-1 may also improve the effectiveness of certain vaccines, especially inactivated vaccines that are safer but may produce weaker immune responses. It is also being studied for sepsis, where it may help regulate excessive inflammation and reduce complications.
Research in mice suggests that thymosin alpha-1 may support brain development by promoting neuron growth and connections between nerve cells. It may also reduce inflammation in the brain, creating an environment that supports healthy development. These findings have led to interest in its possible use for conditions involving delayed brain development.
Thymosin alpha-1 helps dendritic cells mature, improving the immune system’s ability to recognize and fight fungal infections. In mouse studies, it activated T-helper cells against aspergillus, suggesting that it may improve the effectiveness of antifungal treatments.
Thymosin alpha-1 has been studied as an immune-supporting treatment for chronic hepatitis B and C. It may also improve immune responses to hepatitis vaccines and has been approved for hepatitis treatment in several countries.
Thymosin alpha-1 may help regulate immune function and reduce ongoing inflammation in people receiving HIV treatment. It may also encourage CD8 T-cells to release substances that help limit HIV activity and spread.
Research suggests that thymosin alpha-1 may inhibit angiotensin-converting enzyme (ACE), which plays a role in blood pressure regulation. This has led researchers to investigate its possible effects on blood vessel relaxation, heart health, and kidney function.
Studies in cancer cells and animals suggest that thymosin alpha-1 may slow cancer growth and spread while supporting immune responses against tumors. It has also been studied in combination with chemotherapy and for cancers such as breast, melanoma, liver, lung, and colon cancer.
Thymosin alpha-1 may reduce inflammatory pain by lowering the production of cytokines and other molecules involved in inflammation. Animal studies suggest that it may help relieve inflammation-related pain, although further research is needed.
Cystic fibrosis causes excessive inflammation, mucus buildup, and frequent infections. Thymosin alpha-1 may help reduce inflammation and support the function of CFTR, the faulty protein involved in the condition. These possible benefits are being investigated in ongoing research.
Thymosin alpha-1 may support healing when a knocked-out tooth is replanted by helping repair the gums and surrounding tissues. More research is needed to determine its effectiveness in dental injuries.
Thymosin alpha-1 is being studied for its possible applications in immune disorders, infections, cancer, inflammation, and tissue repair. Researchers continue to investigate how it can be used safely and effectively in different medical settings.